Caplin Point Laboratories rose 2.74% to Rs 1,230.55 at 10:17 IST on BSE after consolidated net profit rose 27.2% to Rs 16.13 crore on 21.32% growth in income from operations to Rs 85.07 crore in Q1 June 2016 over Q1 June 2015.
The result was announced after market hours on Friday, 5 August 2016.Meanwhile, the BSE Sensex was up 114.12 points, or 0.41%, to 28,192.47.
On BSE, so far 3,874 shares were traded in the counter, compared with average daily volume of 3,314 shares in the past one quarter. The stock hit a high of Rs 1,270 and a low of Rs 1,220 so far during the day. The stock hit a record high of Rs 1,639 on 3 September 2015. The stock hit a 52-week low of Rs 835.25 on 12 February 2016. The stock had outperformed the market over the past 30 days till 5 August 2016, rising 13.82% compared with 3.22% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 27.31% as against Sensex's 11.30% rise.
The small-cap company has an equity capital of Rs 15.11 crore. Face value per share is Rs 10.
On a consolidated basis, Caplin Point Laboratories' earnings before interest, taxes, depreciation and amortization (EBITDA) rose 21% to Rs 23.83 crore in Q1 June 2016 over Q1 June 2015.
EBITDA margin were reported at 28% in Q1 June 2016, in line with 28% reported in Q1 June 2015.
Meanwhile, the company's board of directors approved for 5-for-1 stock split proposal.
Caplin Point Laboratories is a pharmaceutical company, catering predominantly to emerging markets of Latin America and Africa.
Powered by Capital Market - Live News